Gao, J., Ward, J., Pettaway, C., Shi, L., Subudhi, S., Vence, L., … Sharma, P. (2017). VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 23(5), 551-555. https://doi.org/10.1038/nm.4308